X0609 4 2026-08-06 true 0002058707 Attovia Therapeutics, Inc. ATTO 0001862109 venBio Global Strategic Fund IV, L.P. false 1700 OWENS STREET SUITE 595 SAN FRANCISCO CA 94158 false false true false false Common Stock 2026-08-06 4 C false 2311870 A 2311870 D Common Stock 2026-08-06 4 C false 821998 A 3133868 D Common Stock 2026-08-06 4 C false 665147 A 3799015 D Common Stock 2026-08-06 4 P false 382352 17 A 4181367 D Series A Preferred Stock 2026-08-06 4 C false 21477273 0 D Common Stock 2311870 0 D Series B Preferred Stock 2026-08-06 4 C false 7636362 0 D Common Stock 821998 0 D Series C Preferred Stock 2026-08-06 4 C false 6179219 0 D Common Stock 665147 0 D In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration. These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV. venBio Global Strategic Fund IV, L.P., by: venBio Global Strategic GP IV, LLC, its general partner, by: /s/ David Pezeshki, as attorney-in-fact 2026-08-10